Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Christine Bundy Photo

Christine

Bundy

,

PhD, AFBPS, C Psychol

Professor of Behavioural Medicine
University of Cardiff
Cardiff
,
United Kingdom
Councilor Since: October 1, 2014
IPC Councilor
Request an Update
Dr. Christine Bundy is an applied Health Psychologist. She has conducted translational research over the last forty years, using psychology to improve patient care. Dr. Bundy focuses on the role of beliefs about illness and its treatment and how this impacts mood, particularly health anxiety, and health behaviour through interventions that support motivation for self-management. She designs and delivers psychological interventions for mood management and behaviour change in long-term inflammatory conditions. She also trains psychological support and motivational interviewing skills to health care staff as part of their routine consultations.

Dr. Bundy was President of the United Kingdom Society for Behavioural Medicine from December 2014 to 2016 and served on two NICE clinical guideline development groups plus three research Priority Setting Partnership groups. She has worked on two European Union (EU) Guideline development groups and served as the Behavioural Scientist for the International Intelligence Technical Advisory Group for the Welsh Government during the acute phase of the Covid-19 pandemic.

Dr. Bundy has over 150 peer-reviewed publications, including four key reports on developing National Health Service (NHS) patient services. She leads or collaborates with the National Institute for Health and Care Research (NIHR), industry, and patient charity partners, and her research awards total over £24M.
Last Updated:
04/04/2025

Areas of Interest

Psoriasis and Psoriatic arthritis, patient behavior change and clinician training / education to address psychological issues (PsoWell) GRIDD (New global measure of the impact of living with a skin condition).

Languages Spoken

English

Involvement with Other Organization(s)

In close association with Psoriasis Association of GB and NI; has served on the NICE guideline development group.
Recent publications

Featured

Blog

Prioritizing Mental Health and Illness Beliefs in Psoriasis Care.

Prof. Christine Bundy shares how clinicians can center mental health in psoriasis care — and what to look out for in…

Read More

PDF

Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis,…

View Report

PDF

Getting Under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in Psoriasis.

View Report

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026